Indications:
●Prevention and treatment of osteoporosis in postmenopausal women help strengthen bone mineral density and lower the incidence of vertebral fractures.
●Risk reduction of invasive breast cancer in postmenopausal women with osteoporosis and high-risk postmenopausal women.
Administration Guidelines
Oral Administration:
●Raloxifene is administered orally with or without meals. The recommended dosage typically consists of a daily 60 mg tablet, although varying dosages may be prescribed based on the patient's medical condition, response to treatment, and the prescribing doctor's judgment.
Dosage Forms:
●60 mg oral tablets are typically prescribed to be taken once daily. Consistency in the time of day taken may enhance the medication's efficacy and stability of therapeutic effects.
Safety Preclusions
Pregnancy and Breastfeeding:
●Raloxifene is contraindicated during pregnancy and breastfeeding. It falls under FDA pregnancy category X, indicating that it can harm the fetus and therefore should not be used during pregnancy. Similarly, it should not be administered to nursing mothers to prevent adverse effects on the infant.
Long-term Use:
●Long-term use of raloxifene requires careful monitoring of the patient’s health, including regular assessments of bone mineral density and comprehensive evaluations of the potential risks of prolonged therapy, such as blood clots and stroke.
Drug Interactions:
●Raloxifene should be used cautiously with other medications, particularly those known to affect blood clotting such as warfarin, as well as other hormone replacement therapies and supplements like black cohosh which might alter its effects.
|
Reviews
There are no reviews yet.